Method and composition for treating hunter syndrome by lateral ventricle administration

Administering iduronic acid-2-sulfatase beta to the lateral ventricle of Hunter syndrome patients every four weeks addresses the limitations of current therapies by effectively reducing GAG accumulation and improving brain function, particularly memory and learning abilities.

JP2024160232APending Publication Date: 2024-11-13MEDIGENEBIO CORP +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024112458
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-05-30
Filing Date
2024-07-12
Publication Date
2024-11-13

AI Technical Summary

Technical Problem

Current enzyme replacement therapies for Hunter syndrome, such as Elaprase, are costly and ineffective in treating central nervous system symptoms due to limited distribution across the blood-brain barrier, and direct intrathecal administration has not been successful in terms of stability and effectiveness.

Method used

Administering iduronic acid-2-sulfatase beta into the lateral ventricle of patients with Hunter syndrome every four weeks to target the central nervous system, reducing GAG accumulation and improving brain function.

Benefits of technology

The method effectively suppresses brain function decline, restores damaged brain structures, and improves memory and learning functions, demonstrating better therapeutic effects than single-dose administration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024160232000005
    Figure 2024160232000005
  • Figure 2024160232000006
    Figure 2024160232000006
  • Figure 2024160232000007
    Figure 2024160232000007
Patent Text Reader

Abstract

To provide a pharmaceutical composition for treating Hunter syndrome.SOLUTION: A pharmaceutical composition reduces or inhibits cerebral ventricle enlargement of a subject having Hunter syndrome or improves brain function or learning memory ability of the subject having Hunter syndrome or suppresses hyperactive characteristic of the subject having Hunter syndrome, contains iduronic acid-2-sulfatase beta (IDS-β). The pharmaceutical composition is administered to a lateral ventricle once every four weeks, where administration does not cause a serious harmful effect in the subject, and administration reduces accumulation of heparan sulfate (HS) in brain cells or cerebrospinal fluid of the subject, reduces cell vacuolation in the brain cells of the subject, and inhibits expression of lysosomal-associated membrane protein 2 (LAMP2) in the brain cells of the subject.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to methods and pharmaceutical compositions for treating Hunter Syndrome. [Background technology]

[0002] Hunter syndrome, or mucopolysaccharidosis type II, is a lysosomal storage disease (LSD) in which deficiency of iduronate-2-sulfatase (IDS or I2S) prevents mucopolysaccharides such as glycosaminoglycans (GAGs) from being broken down in the body, leading to their accumulation in lysosomes. GAGs accumulate in cells throughout the body, causing a variety of symptoms. Symptoms include prominent facial features, macrocephaly, abdominal distension due to enlarged liver or spleen, along with hearing loss, heart valve disease, obstructive respiratory disease, and sleep apnea. In addition, accumulated GAGs may also restrict joint movement and, if the central nervous system is affected, may cause neurological symptoms and developmental delays. Hunter syndrome is known to occur in approximately 1 in 162,000 live births and is inherited in an X-linked recessive pattern.

[0003] Enzyme replacement therapy (ERT), one of the treatment methods for Hunter syndrome, is a method in which exogenously produced IDS is administered into the body. This method has the advantage of being simple to administer, but has the disadvantage of high treatment costs because the enzyme needs to be administered continuously. Elaprace (registered trademark) (Shire Pharmaceuticals Group), a recombinant enzyme replacement therapy approved by the US FDA, is on the market, but has the disadvantages of being very expensive and showing low efficacy and safety.

[0004] Enzyme replacement therapy is achieved by systemic administration of natural or recombinantly derived proteins and / or enzymes to a subject. Approved enzyme replacement therapies are usually administered intravenously and are generally effective in treating physical symptoms resulting from enzyme deficiencies that are the cause of a disease or condition. However, these enzyme replacement therapies suffer from limited distribution of intravenously administered proteins and / or enzymes to cells and tissues of the central nervous system (CNS). Particularly in the treatment of diseases with CNS etiology, such enzyme replacement therapies have been problematic because intravenously administered proteins and / or enzymes do not cross the blood-brain barrier (BBB).

[0005] To overcome these problems with the blood-brain barrier, attempts have been made to develop treatments in which proteins and / or enzymes are administered directly into the subject's cerebrospinal fluid by intrathecal (IT) injection, but such attempts have yet to be successful in terms of stability and efficacy.

[0006] Thus, there is a need for the development of treatments that can effectively treat Hunter syndrome patients with central nervous system disorders, ultimately resulting in improved brain function in these patients.

[0007] The present inventors have discovered that when iduronate-2-sulfatase beta is repeatedly administered to the lateral ventricles of a subject over a long period of time, such administration has a surprising effect of suppressing and improving the decline in brain function seen in patients with Hunter syndrome, and thus have completed the present invention. Summary of the Invention [Problem to be solved by the invention]

[0008] It is an object of the present invention to provide therapeutic methods and pharmaceutical compositions for substantially treating or ameliorating central nervous system degeneration, particularly brain decline, caused by Hunter Syndrome. [Means for solving the problem]

[0009] To achieve the above objectives, the present invention provides a pharmaceutical composition for treating Hunter syndrome in a subject, comprising iduronate-2-sulfatase beta and administered into the lateral ventricle once every four weeks, and a method for treating Hunter syndrome using the pharmaceutical composition. Effect of the Invention

[0010] The pharmaceutical composition according to the present invention has the effect of actually improving brain function in subjects suffering from Hunter syndrome, and it has been confirmed in the present invention that administration of such a composition can sufficiently suppress the loss of brain function in clinical practice.

[0011] In addition, the pharmaceutical composition according to the present invention administered repeatedly over a long period of time has a better therapeutic effect against Hunter syndrome than when the same dose of the active ingredient is given by a single administration, and further has effects that cannot be predicted from the results obtained by a single administration, such as treatment or restoration of damaged brain structures, and substantial treatment or improvement of brain functions, in particular improvement of memory and learning functions. [Brief description of the drawings]

[0012] [Figure 1] FIG. 1 is a diagram showing the location where a formulation according to an embodiment of the present invention was administered in Test Example 1, the location shown being the mouse lateral ventricle. [Diagram 2] Photographs showing the extraction of cerebrospinal fluid from a mouse brain in Test Example 2. The photograph on the far right shows cerebrospinal fluid collected in a micropipette. [Diagram 3] 1 is a graph showing the results of Test Example 2, showing the amount of heparan sulfate (HS) accumulated in the mouse brain and cerebrospinal fluid. [Figure 4] FIG. 1 is a graph showing the results of Test Example 2, showing a comparison of the amount of HS accumulated in the brain and cerebrospinal fluid of mice at 28 days after a single administration and at 28 days after six repeated administrations according to the Example. [Figure 5a]FIG. 5a is a photograph obtained by brain magnetic resonance imaging of a mouse, which is the result of Test Example 3; FIG. 5b is a graph showing the ratio of ventricular volume to total brain volume in a mouse. [Figure 5b] FIG. 5a is a photograph obtained by brain magnetic resonance imaging of a mouse, which is the result of Test Example 3; FIG. 5b is a graph showing the ratio of ventricular volume to total brain volume in a mouse. [Figure 6] 1 is a photograph showing the results of Test Example 4, which shows the results obtained by hematoxylin-eosin staining of mouse brain tissue. [Figure 7] 1 is a photograph showing the results of Test Example 5, which shows the results obtained by immunohistochemical staining of mouse brain tissue. [Figure 8] 1 is a graph showing the results of Test Example 6, which shows the results obtained by carrying out a fear conditioning test to evaluate the learning and memory ability of mice. [Figure 9] 1 is a graph showing the results of Test Example 7, which shows the results obtained by performing an open field test to evaluate the hyperactivity characteristics of mice. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] definition In order to better understand this invention, certain terms are defined below: Further explanations of the following terms, as well as other terms, can be found throughout the specification.

[0014] As used herein, the term "about" when applied to one or more numerical values ​​means a numerical value similar to the stated reference numerical value. In one aspect of the present invention, the term "about" means a range of numerical values ​​that includes 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater or less) of the stated numerical value (except where such number exceeds 100% of the possible numerical values), unless otherwise stated or the context clearly indicates otherwise.

[0015] As used herein, the term "treatment" refers to any administration of a therapeutic protein (e.g., a lysosomal enzyme) that results in partial or complete alleviation, reversal, relief, suppression, delayed onset, reduced severity and / or reduced incidence of one or more symptoms or characteristics of a particular disease, disorder, and / or condition (e.g., Hunter Syndrome). Such treatment may be applied to subjects who do not exhibit symptoms of the associated disease, disorder, and / or condition and / or to subjects who exhibit only early symptoms of the disease, disorder, and / or condition. Optionally or additionally, such treatment may be applied to subjects who exhibit one or more established symptoms of the associated disease, disorder, and / or condition.

[0016] The present invention will now be described in detail.

[0017] In one aspect, the present invention may be directed to a pharmaceutical composition comprising iduronate-2-sulfatase beta ("IDS-β").

[0018] In one aspect of the invention, the pharmaceutical composition may be for treating Hunter Syndrome in a subject.

[0019] In one aspect of the invention, the pharmaceutical composition may be for treating or inhibiting ventricular enlargement in a subject suffering from Hunter syndrome.

[0020] In one aspect of the invention, the pharmaceutical composition may be for improving brain function in a subject suffering from Hunter Syndrome.

[0021] In one aspect of the invention, IDS-β may comprise a protein having the amino acid sequence of SEQ ID NO: 1, which is a recombinant human iduronate-2-sulfatase protein. In one aspect of the invention, IDS-β may further comprise a protein having the amino acid sequence of SEQ ID NO: 2, which is a recombinant human iduronate-2-sulfatase protein in which the cysteine ​​at amino acid position 59 has been replaced with formylglycine (Fgly).

[0022] In one aspect of the present invention, IDS-β may contain about 20-35 mol % or less of a protein having the amino acid sequence of SEQ ID NO: 1 and about 65-80 mol % or less of a protein having the amino acid sequence of SEQ ID NO: 2. In particular, in one aspect of the present invention, IDS-β may contain about 35 mol % or less of a protein having the amino acid sequence of SEQ ID NO: 1 and about 65 mol % or less of a protein having the amino acid sequence of SEQ ID NO: 2.

[0023] In one aspect of the invention, IDS-β may comprise a protein having an amino acid sequence that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98% identical to SEQ ID NO: 1. In one aspect of the invention, IDS-β may comprise a protein having an amino acid sequence that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98% identical to SEQ ID NO:2.

[0024] In one embodiment of the invention, IDS-β may be at a concentration of about 0.1 mg / ml to about 60 mg / ml, about 1 mg / ml to about 10 mg / ml, or about 6 mg / ml.

[0025] In one embodiment of the present invention, the dose of IDS-β in a single administration may be about 1 μg to 60 μg, about 15 μg to about 60 μg, about 20 μg to about 40 μg, about 25 μg to about 35 μg, about 29 μg to about 31 μg, or about 30 μg; such a dose may be the dose when administered to a mammal such as a mouse. However, the present invention is not limited thereto. In addition, in one embodiment of the present invention, the dose of IDS-β in a single administration may be about 1 mg to 60 mg, about 15 mg to about 60 mg, about 20 mg to about 40 mg, about 25 mg to about 35 mg, about 29 mg to about 31 mg, or about 30 mg; such a dose may be the dose when administered to a human. However, the present invention is not limited thereto.

[0026] In one embodiment of the invention, the pharmaceutical composition may be administered to the subject's lateral ventricle once every four weeks.

[0027] In one aspect of the invention, the pharmaceutical composition may be administered directly to either or both of the lateral ventricles of a subject.

[0028] In one aspect of the invention, administration of the pharmaceutical composition may reduce or inhibit ventricular enlargement in a subject with Hunter syndrome; improve brain function in the subject; improve learning and memory abilities in the subject; suppress hyperactive traits in the subject; reduce cellular vacuolization in brain cells; or inhibit expression of lysosomal associated membrane protein 2 (LAMP2) in brain cells.

[0029] In one aspect of the invention, administration of the pharmaceutical composition may reduce heparan sulfate (HS) accumulation in the brain (e.g., brain cells) or cerebrospinal fluid of a subject. In one aspect of the invention, HS accumulation may be reduced by 20%, 40%, 50%, 60%, 80%, 90%, 1-fold, 1.5-fold, 2-fold, or 3-fold compared to a control.

[0030] In one embodiment of the invention, the pharmaceutical composition can be administered to the subject three or more times. In one embodiment of the invention, the pharmaceutical composition can be administered three or more times, four or more times, five or more times, six or more times, seven or more times, eight or more times, nine or more times, or ten or more times; in particular, six times to the subject.

[0031] In one embodiment of the invention, the pharmaceutical composition may be administered for 12 weeks or more and 48 weeks or less. In one embodiment of the invention, the pharmaceutical composition may be administered for 12 weeks or more, 16 weeks or more, 20 weeks or more, 24 weeks or more, 28 weeks or more, 32 weeks or more, 36 weeks or more, 40 weeks or more, 44 weeks or more, or 48 weeks or more; in particular for 24 weeks.

[0032] In one aspect of the invention, the subject may be a human or a mammal. In one aspect of the invention, the mammal may be a mouse, rat, rodent, cat, rabbit, dog, pig, horse, or cow.

[0033] In one embodiment of the present invention, the pharmaceutical composition can be administered through an intraventricular catheter system that includes a reservoir and a catheter connected to the reservoir. In the test example described below, the pharmaceutical composition was administered to mice, so an individual three-dimensional positioning device and a three-dimensional positioning coordinate system were required. However, in clinical applications, the pharmaceutical composition of the present invention can be administered through a simple intraventricular catheter system.

[0034] In one aspect of the invention, administration of the pharmaceutical composition can be performed in a manner comprising the steps of: 1) surgically inserting a catheter system in which a reservoir is placed under the subject's scalp and an end of a catheter is placed within the subject's lateral ventricle such that the lateral ventricle cavity is connected to the reservoir cavity via the catheter cavity, thereby allowing cerebrospinal fluid to flow from the lateral ventricle into the reservoir and causing the reservoir to fill with cerebrospinal fluid; 2) withdrawing approximately 0.1-5 ml of cerebrospinal fluid from the reservoir at a rate of 0.1-60 ml / min; 3) injecting 0.1-5 ml of the pharmaceutical composition into the reservoir at a rate of 0.1-60 ml / min; and 4) allowing the pharmaceutical composition to flow from the reservoir into the lateral ventricle via the catheter.

[0035] In one aspect of the present invention, the administration of the pharmaceutical composition may be performed in conjunction with one or more additional enzyme replacement therapies for treating Hunter syndrome.In particular, in one aspect of the present invention, the additional enzyme replacement therapy may be at least one of intravenous and subcutaneous administration of IDS-β.Such intravenous and subcutaneous administration may refer to conventional administration methods; in clinical application, the administration to the lateral ventricle of the present invention does not need to set the limit of administration schedule.

[0036] In one aspect of the invention, the pharmaceutical composition may further comprise sodium chloride and polysorbate 20, and may have a pH of about 5 to about 7. In one aspect of the invention, the pharmaceutical composition may have a pH of about 6.

[0037] In one embodiment of the present invention, the sodium chloride contained in the pharmaceutical composition may be at a concentration of about 100 mM to about 200 mM. Here, the concentration of sodium chloride may correspond to any integer range within the above range. In particular, the sodium chloride may be at a concentration of about 150 mM.

[0038] In one embodiment of the present invention, the polysorbate 20 contained in the pharmaceutical composition may have a concentration of about 0.01 mg / ml to 0.5 mg / ml. Here, the concentration of polysorbate 20 may correspond to all decimal ranges present within the above range. In particular, polysorbate 20 may have a concentration of about 0.05 mg / ml. In one embodiment of the present invention, administration of the pharmaceutical composition does not cause serious adverse effects. In one embodiment of the present invention, serious adverse effects may mean, but are not limited to, any effect that causes a substantial immune response, toxicity, or death.

[0039] As used herein, the term "substantial immune response" can mean a profound or significant immune response, such as a substantial T cell-mediated adaptive immune response.

[0040] In one aspect of the present invention, the pharmaceutical composition can be provided in a container, such as a vial, a syringe, or a prefilled syringe, and when administered in a single dose, can be provided in a disposable plastic syringe. In one aspect of the present invention, the pharmaceutical composition can be administered in a volume of about 1 μL to about 10 μL, a volume of about 3 μL to about 7 μL, a volume of about 4 μL to about 6 μL, or a volume of about 5 μL; however, the present invention is not limited thereto. In addition, in one aspect of the present invention, the pharmaceutical composition can be administered in a volume of about 1 mL to about 10 mL, a volume of about 3 mL to about 7 mL, a volume of about 4 mL to about 6 mL, or a volume of about 5 mL; however, the present invention is not limited thereto.

[0041] In one aspect, the present invention may be directed to a pharmaceutical composition for treating or inhibiting ventricular enlargement in a subject suffering from Hunter syndrome, comprising about 150 mM sodium chloride, about 0.05 mg / ml polysorbate 20, and about 5 mg / ml iduronate-2-sulfatase beta (IDS-β), wherein the pharmaceutical composition has a pH of about 6 and is administered into the lateral ventricle once every four weeks.

[0042] In one aspect, the present invention may be directed to a pharmaceutical composition for improving brain function in a subject suffering from Hunter syndrome, comprising about 150 mM sodium chloride, about 0.05 mg / ml polysorbate 20, and about 5 mg / ml iduronate-2-sulfatase beta (IDS-β), wherein the pharmaceutical composition has a pH of about 6 and is administered into the lateral ventricle once every four weeks.

[0043] In one aspect, the present invention provides a method for treating Hunter Syndrome, comprising the step of applying to a subject a pharmaceutical composition of the present invention.

[0044] In one aspect of the present invention, there is provided a use of the pharmaceutical composition of the present invention for treating Hunter Syndrome.

[0045] In one aspect of the invention there is provided a use of a pharmaceutical composition of the invention for the manufacture of a medicament for treating Hunter Syndrome. EXAMPLES

[0046] The configuration and effects of the present specification will be described in more detail below with reference to examples and test examples. However, these examples and test examples are provided for illustrative purposes only to help understand the present specification, and the scope of the present specification is not limited by the following examples.

[0047] [Preparation Example 1] Preparation of IDS-β formulation for administration As the carrier solution, 150 mM sodium chloride and 0.05 mg / ml Tween 20 solution (Merck Millipore, Darmstadt, Germany) was used. An IDS-β solution (50 mg / ml or 15 mg / ml) obtained from Green Cross Co., Ltd. was diluted with the above carrier solution to prepare an IDS-β formulation at a concentration of 6 mg / ml. The IDS-β formulation thus prepared was used in the following test examples.

[0048] [Test Example 1] Administration to the lateral ventricle in mice animal The mice used in the experimental examples described herein were in-house-produced mice, which were produced to have a partial deletion of the iduronate-2-sulfatase (IDS) gene. Briefly, the deletion of the IDS gene was made from exons 2-3. IDS KO mice (IDS knockout mice) were bred from a C57BL / 6.129S background strain and had a silent mutation in the IDS gene. Wild-type (WT) control mice were bred from the C57BL / B6.129S strain. All mice were genotyped by polymerase chain reaction (PCR) using DNA obtained from tail snips. The experimental examples described herein were approved by the Institutional Animal Care and Use Committee (approval number 20140925005) and were conducted in accordance with the animal welfare policy of the Samsung Biomedical Research Institute (Seoul, Korea).

[0049] Mice obtained by breeding were classified and assigned as shown in Table 1 below.

[0050] [Table 1]

[0051] Lateral ventricle injection Mouse brain coordinates are required for accurate lateral ventricle administration. This information is provided in [Paxinos, George and Franklin, Keith BJ, Paxinos and Franklin's The Mouse Brain in Stereotaxic Coordinates, Academic Press, 4th Edition, 2012] and is shown in Figure 1. For the location of the lateral ventricles by mouse age based on weeks, we further referred to [Paxinos, George and Franklin, Keith BJ, Paxinos and Franklin's The Mouse Brain in Stereotaxic Coordinates, Academic Press, 4th Edition, 2012].

[0052] Intraventricular administration was performed on 6-week-old mice obtained by the above breeding. The carrier solution and IDS-β solution of Preparation Example 1 were administered to each group in a single dose at a volume of 5 μL. On the day of administration, the mice were anesthetized with isoflurane (HANA PHARM CO.,LTD., Korea) by inhalation and placed in a stereotaxic apparatus (Stoelting, USA). Next, the scalp of the mice was minimally peeled off and the exposed skull was cleaned. The carrier solution and IDS-β solution prepared in Preparation Example 1 were each placed in a disposable plastic syringe and injected into the lateral ventricle of the mice through a 31-gauge needle at a constant rate of 10 μL / min using a syringe pump (KD Scientific, Switzerland). During administration, the position of the injection needle in the brain was monitored using stereotaxic coordinates (Stoelting, USA). The needle coordinates at the start of administration were as follows: -0.58 mm caudal to bregma, 1.25 mm lateral to the sagittal suture, and -1.77 mm deep. After administration of a volume of 5 μL was completed, the needle was lifted 0.15 mm per 30 seconds 4-5 times to remove it from the injection site. Next, the needle was lifted from the -1.00 mm depth position at a height of 0.3 mm per 30 seconds several times to completely remove the needle. These actions were introduced to prevent backflow of the administered solution, and the time required for the entire administration process was approximately 30 min per subject. After administration, the exposed skin area, including the injection site, was simply sutured with a medical stapler.

[0053] After this administration, the mice did not show any significant adverse effects. No subject dropouts due to substantial immune responses at the administration site, abnormal body functions, etc. were observed. Necropsy was performed 28 days after the last administration date, and the following analyses were performed.

[0054] [Test Example 2] Analysis of HS accumulated in mouse brain or cerebrospinal fluid Collection of mouse brain and cerebrospinal fluid At the time of autopsy, 28 days after the final administration date, for each group based on Table 1, cerebrospinal fluid was first collected in the cisternal region of the mouse of interest using a borosilicate glass micropipette (outer diameter: 10 mm, inner diameter: 0.75 mm) (see Figure 2). For HS analysis, the collected cerebrospinal fluid (approximately 5-10 μL) was rapidly frozen using liquid nitrogen immediately after collection and then stored in a cryogenic freezer until analysis. For analysis of heparan sulfate in the brain, transcardial perfusion was performed with phosphate-buffered saline (PBS) and the brain was collected. The collected brain was rapidly frozen and then stored in a cryogenic freezer until analysis.

[0055] HS analysis method Liquid chromatography tandem mass spectrometry (LC-MS / MS) was used to measure HS levels in cerebrospinal fluid and brain tissue samples collected from mice. 2 μL of mouse cerebrospinal fluid or brain tissue samples homogenized in PBS were aliquoted for pretreatment. Each sample was heated in hydrochloric acid-methanol to be methanolized. The methanolysate obtained was evaporated to dryness under a stream of nitrogen gas. Deuterated dermatan sulfate and heparan sulfate (DS-d6 and HS-d6) were used as internal standards. The solution thus obtained was transferred to a centrifugal filter and centrifuged. The filtrate obtained was analyzed. LC-MS / MS analysis was performed using an ultra-performance liquid chromatography system (UPLC, Waters) and a triple quadrupole mass spectrometer (API5000, AB / MDS Sciex). Data were processed using Analyst 1.5.1. software. The analysis results are shown in Figures 3 and 4. Statistical analysis was performed using the Holm-Sidak multiple comparison test (Figures 3 and 4). * :P<0.05, ** :P<0.001, *** :P<0.0001).

[0056] result The amount of HS accumulated in the brain and cerebrospinal fluid in each group was compared. Referring to Figure 3, it was confirmed that HS was maintained at a lower level than Comparative Example 1 at 28 days after the final administration date for the Example of the present invention. These results suggest that the administration cycle of once every 4 weeks shows the effect of inhibiting HS accumulation in that the effect is steadily maintained for one month at the administered dose (see Figure 3).

[0057] Referring to FIG. 4, when comparing the amount of HS reduction between the mice of Comparative Example 2 administered with the same amount of drug as in the single administration and the mice of the Example of the present invention, it was confirmed that the Example of the present invention, which was administered with repeated administration, reduced HS more than the Comparative Example 2, which was administered with a single administration. These results show that even if the same single dose is administered and the single administration is performed to maintain the same period (i.e., 28 days after administration), the continuous administration provides a much better therapeutic effect than the single administration; this has a great impact on clinical therapeutic effects. According to these results, when the same single dose is used, the repeated administration will significantly increase the therapeutic effect of the patient; for this, it is necessary to support the convenience of the patient and the caregiver.

[0058] [Test Example 3] Evaluation of inhibitory effect on ventricular enlargement Brain MRI analysis of mice was performed to confirm whether lateral ventricle administration according to the present invention not only improves HS, a biochemical indicator of the brain and cerebrospinal fluid, but also has the effect of inhibiting structural destruction or damage of the brain.

[0059] Specifically, after six doses were completed, all mice were imaged using a 7.0-Tesla MRI system (Bruker-Biospin, Fallanden, Switzerland), equipped with a 20 cm gradient set capable of delivering up to 400 mT / m with a rise time of 100 ms. A birdcage coil (inner diameter, 72 mm; Bruker Biospin) was used for excitation, and an actively decoupled phased array coil was used for signal reception.

[0060] Mice were anesthetized with isoflurane (HANA PHARM CO.,LTD., Korea) (5% for induction, 2% for animal setup, and 1%-1.5% during MRI experiments) in a mixture of oxygen and nitrogen gases (3:7) delivered to a nose cone for spontaneous breathing throughout the experiment. The head of the mouse was fixed very carefully using bite / ear bars. Coronal images containing the cerebellum were obtained with the following characteristics: T2 weighted, fast spin echo sequence, 192 × 192 matrix size, 19.2 × 19.2 mm. 2 Resolution, TR / TE = 3,000 / 70 ms, NEX = 6, slice thickness 1.0 mm with no interslice gap.

[0061] Nine coronal MRIs were obtained per mouse to assess the percent volume ratio of the ventricles to the whole brain. The percent volume ratio was estimated manually by contouring consecutive images in a blinded fashion using ParaVision 2.0.2 software (Bruker, Biospin, Karlsruhe, Germany). The border between the whole brain and the ventricles was contoured on each image and the corresponding area was calculated using the above software. The ventricular area was calculated as (lateral ventricle area / total brain area). The results are shown in Figure 5 and Table 2.

[0062] result Among Hunter syndrome patients, patients with central nervous system degeneration were accompanied by ventricular enlargement. Similarly, in Hunter syndrome mice (IDS KO mice), ventricular enlargement could be confirmed by brain MRI. In this test example, it was verified whether ventricular enlargement in the untreated group of IDS KO mice was alleviated by administration of the present invention. As a result, it was found that the Example showed a significant reduction in ventricles compared to the untreated group and Comparative Example 1.

[0063] [Table 2]

[0064] [Test Example 4] Evaluation of inhibitory effect on cell vacuolation At the time of autopsy of the mice from each group, sections of the cerebellum, medulla, thalamus, and cortex were collected for histological staining in mouse brain tissue, fixed overnight in 4% paraformaldehyde solution (BIOSESANG, Korea), subjected to histological processing, and then embedded in paraffin. Sections with a thickness of 4 μm were prepared for hematoxylin / eosin (H&E) staining.

[0065] Hematoxylin / eosin staining Brain tissue sections collected from mice in each group were stained with hematoxylin / eosin.

[0066] In particular, the slides with the fixed brain tissue sections were deparaffinized by immersing them in a xylene solution. The slides were then sequentially immersed in ethanol ranging from 100% ethanol to less concentrated ethanol to remove the xylene. The slides were then washed in running water and then stained by immersing in a hematoxylin solution for 5-8 minutes. After staining, the slides were washed in running water, immersed in 1% hydrochloric acid for a period of time, and then washed again in running water. The slides were immersed in a 1% ammonia solution and then washed again in running water. The slides were then stained by immersing them in an eosin solution for 2 minutes. The slides were then dehydrated in an ethanol solution and sealed together with xylene.

[0067] The stained slides were scanned with a ScanScope AT (Aperio, Leica, Germany) device and then analyzed with an ImageScope (Aperio, Leica, Germany) device to evaluate the histopathological morphology. Photographs of the scanned slides are shown in Figure 6.

[0068] result Hematoxylin / eosin staining showed that structural destruction was progressing throughout the brain of the Hunter syndrome mice due to accumulation of glycosaminoglycans (GAGs). In particular, cellular vacuolization, a typical marker of lysosomal storage disease, was observed throughout the mouse brain in the mice with Hunter syndrome of Comparative Example 1 compared to the mice of the Reference Example (see FIG. 6). This cellular vacuolization is indicated by an arrow in the photograph of the stained slide of Reference Example 1 in FIG. 6. On the other hand, it was found that cellular vacuolization was significantly reduced in the area indicated by the arrow in the mice with Hunter syndrome of the Example after administration according to the present invention.

[0069] [Test Example 5] Evaluation of inhibitory effect on LAMP2 protein expression Immunohistochemical staining Brain tissue sections from each group prepared in Test Example 4 were stained with anti-LAMP-2 IgG (Santa Cruz Biotechnology, USA), a primary antibody, and developed by the DAB method to visualize the expression of LAMP2 protein. LAMP2 protein is a lysosome-associated membrane protein and is used as an indicator of lysosomal activity. After development by the DAB method, the brain tissue sections were counterstained with hematoxylin for LAMP2 protein-positive cells and nuclei.

[0070] In particular, 4 μm-thick tissue sections were placed in 10% normal goat serum (Dako, Carpinteria, CA, USA) for 20 min at room temperature, then incubated with anti-LAMP-2 antibody at a ratio of 1:100 for 30 min at room temperature. The tissue sections were washed several times with PBS. Next, the tissue sections were incubated with HRP-labeled polymer-conjugated secondary antibody for 30 min at room temperature. The tissue sections were placed in 3,3-diaminobenzidine substrate-chromogen solution (Dako, Carpinteria, CA, USA) for 5 min and washed with water. Nuclear staining was then performed with hematoxylin.

[0071] The stained slides were scanned with a ScanScope AT (Aperio, Leica, Germany) device and then analyzed with an ImageScope (Aperio, Leica, Germany) device to evaluate the histopathological morphology. Photographs of the scanned slides are shown in Figure 7.

[0072] result 7, it was found that the mice with Hunter syndrome of Comparative Example 1 showed significantly higher expression levels of LAMP2 protein, which is a marker of lysosomal activity and disease state in brain cells and perivascular cells, compared to the mice of the Reference Example. On the other hand, it was found that the mice with Hunter syndrome of the Example showed significantly inhibited expression levels of LAMP2 protein throughout the brain tissue after administration according to the present invention.

[0073] [Test Examples 6 and 7] Behavioral evaluation of mice to evaluate improvement of brain function In order to identify the actual effect of administration of the present invention on brain function, fear conditioning test and open field test are carried out, which are tests for evaluating learning and memory ability in the behavioral evaluation of animals.These two behavioral evaluation items can be used to evaluate the overall brain function by evaluating the exploration ability or movement of small animals such as rodents, and the degree to which small animals can cope with sufficiently expected environmental changes.The method for carrying out each test and the test results are as follows.

[0074] [Test Example 6] Fear conditioning test Two to three weeks after the lateral ventricle administration of Test Example 1 (after the first, third and sixth administrations), the fear memory of the mice belonging to each group was evaluated using the following fear conditioning system (Coulbourn Instruments): On the first day of evaluation, the mice were stimulated in the fear conditioning chamber with a 30-second auditory cue (80 dB, 3600 Hz tone) as the conditioned stimulus and a 2-second foot shock (0.6 mA direct current) as the unconditioned stimulus. On the second day of evaluation, 24 hours later, the mice were returned to the same chamber and videotaped for 300 seconds at a frequency of 40 Hz (30 frames per 0.75 seconds) to evaluate associative memory. One hour after the evaluation of associative memory, the mice were placed in a new separate chamber and stimulated with an auditory cue to evaluate the cued memory of the mice. The movements of the mice were similarly videotaped for 300 seconds at a frequency of 40 Hz (30 frames per 0.75 seconds).

[0075] The recorded videos were post-mortem analyzed using Freeze Frame Software Ver 3.32, which automatically calculated the motion index and relative absence of motion. The freezing time was counted when the mouse showed a bout of relative motionlessness longer than 0.75 seconds or 2 seconds. This freezing time was divided by the total observation time (300 seconds). The obtained values ​​were expressed as percentages, and the graphs of the contextual conditioning and cue-dependent conditioning items are shown in Figure 8. The specific results are shown in Table 3.

[0076] [Table 3]

[0077] result Referring to FIG. 8, it can be seen that as the administration proceeded, the mice of the embodiment showed significantly better learning and memory abilities compared to the mice of Comparative Example 1. After the final sixth administration, the brain function of the mice of the embodiment had improved to the extent that they showed learning and memory abilities close to those of normal mice. It can be seen that starting from the third administration, clear improvements were observed in both the "contextual conditioning" item, in which associative memory (to evaluate visual and auditory memory) is measured in the test space, and the "cue-dependent conditioning" item, in which fear memory for repeated fear stimuli is evaluated (see FIG. 8 and Table 3).

[0078] [Test Example 7] Open field test After administration of Test Example 1 into the lateral ventricle (after the first, third and sixth administrations), the exploratory behavior of the mice in each group was evaluated using the following open field test: the mice were allowed to explore an open-top arena (44.5 cm x 44.5 cm) with opaque side walls (height 15.0 cm), and the movements of the mice were videotaped for 20 minutes. The recorded videos were analyzed for exploration distance, movement speed, rest time, time spent in the central and peripheral zones, and frequency of entry into each zone. The central zone represents the 31.0 cm x 31.0 cm area marked in the center of the arena, and the peripheral zone represents the remaining area excluding the central zone. Graphs of the respective analysis results are shown in Figure 9, and specific result values ​​are shown in Table 4.

[0079] result Hunter syndrome mice are known to usually exhibit hyperactivity. This was also confirmed by the results of the open field test of the present invention. 20 minutes of observation showed that the total distance traveled throughout the entire section (i.e., horizontal path distance) steadily increased in the mice of Comparative Example 1. However, it was found that the total distance traveled decreased in the mice of the Example, indicating suppression of hyperactivity. In the same sense, the mice of Comparative Example 1 also showed a tendency to decrease the resting time during which they were motionless, while the mice of the Example showed an increase in the resting time.

[0080] In a certain space, rodents have an instinct to prefer the sides that are more likely to protect them from predators such as birds than the center. Therefore, in the open field test, it is a common behavioral characteristic of mice to explore the peripheral zone rather than the central zone of a prepared space. However, it was found that the mice of Comparative Example 1 showed an increase in the frequency of central entry and the time spent in the central zone with aging. On the other hand, the mice of the embodiment showed the same tendency as the mice of the reference example, which are normal mice.

[0081] [Table 4]

Claims

1. 1. A pharmaceutical composition for reducing or inhibiting ventricular enlargement in a subject with Hunter Syndrome, improving brain function or learning and memory ability in a subject with Hunter Syndrome, or suppressing hyperactivity in a subject with Hunter Syndrome, comprising: Iduronate-2-sulfatase beta (IDS-β) Including, the pharmaceutical composition is administered into the lateral ventricle once every four weeks; said administration does not cause serious adverse effects in said subject; and the administration reduces accumulation of heparan sulfate (HS) in brain cells or cerebrospinal fluid of the subject; reduces cellular vacuolization in brain cells of the subject; or inhibits expression of lysosomal-associated membrane protein 2 (LAMP2) in brain cells of the subject. Pharmaceutical compositions.

2. The pharmaceutical composition of claim 1 , wherein the administration is directly into either or both of the subject's lateral ventricles.

3. 2. The pharmaceutical composition of claim 1, wherein the HS accumulation is reduced by 20%, 40%, 50%, 60%, 80%, 90%, 1-fold, 1.5-fold, or 2-fold compared to a control.

4. The pharmaceutical composition of claim 1 , wherein the administration is performed three or more times to the subject.

5. The method of claim 1 , wherein the administration is for more than 12 weeks and less than 48 weeks.

6. The pharmaceutical composition of claim 1 , wherein the subject is a mammal, a human, or a mouse.

7. The pharmaceutical composition of claim 6 , wherein the subject is a mouse.

8. The pharmaceutical composition of claim 1 , wherein the administration is performed through an intraventricular catheter system comprising a reservoir and a catheter connected to the reservoir.

9. Administering: 1) surgically inserting the catheter system such that the reservoir is placed under the subject's scalp and an end of the catheter is placed within a ventricle of the subject, such that the intraventricular cavity is coupled to a reservoir cavity via the catheter cavity, thereby allowing cerebrospinal fluid to flow from the ventricle to the reservoir and causing the reservoir to fill with cerebrospinal fluid; 2) withdrawing about 0.1-5 ml of the cerebrospinal fluid from the reservoir at a rate of 0.1-60 ml / min; 3) injecting 0.1-5 ml of the pharmaceutical composition into the reservoir at a rate of 0.1-60 ml / min; and 4) allowing the pharmaceutical composition to flow from the reservoir through the catheter into the ventricle. The pharmaceutical composition according to claim 8, wherein the composition is administered in a manner comprising the steps of:

10. 2. The pharmaceutical composition of claim 1, wherein the administration is in conjunction with one or more additional enzyme replacement therapies for treating Hunter syndrome.

11. The pharmaceutical composition of claim 10, wherein the additional enzyme replacement therapy is at least one of intravenous and subcutaneous administration of IDS-β.

12. 2. The pharmaceutical composition of claim 1, wherein the IDS-β is at a concentration of about 0.1 mg / ml to about 60 mg / ml, or about 1 mg / ml to about 10 mg / ml, or 6 mg / ml.

13. 2. The pharmaceutical composition of claim 1, wherein the dose of IDS-β in a single administration is from about 15 μg to about 60 μg, or from about 20 μg to about 40 μg, or about 30 μg.

14. 2. The pharmaceutical composition of claim 1, wherein the dose of IDS-β in a single administration is from about 1 mg to about 60 mg, or from about 15 mg to about 60 mg, or from about 20 mg to about 40 mg, or about 30 mg.

15. Sodium chloride; and Polysorbate 20 Further comprising:

2. The pharmaceutical composition of claim 1 having a pH of 5 to 7.

16. 16. The pharmaceutical composition of claim 15, wherein the sodium chloride is at a concentration of about 100 mM to about 200 mM and the polysorbate 20 is at a concentration of about 0.01 mg / ml to 0.5 mg / ml.

17. 2. The pharmaceutical composition of claim 1, wherein the serious adverse effect is a substantial T cell-mediated adaptive immune response, toxicity, or death.

18. 1. A pharmaceutical composition for treating or inhibiting ventricular enlargement or improving brain function in a subject suffering from Hunter syndrome, comprising: About 150 mM sodium chloride; About 0.05 mg / ml polysorbate 20; and Approximately 6 mg / ml of iduronate-2-sulfatase beta (IDS-β) Including, A pharmaceutical composition having a pH of about 6 and administered into the lateral ventricle once every four weeks.

19. Applying the pharmaceutical composition of claim 1 to a subject.

23. A method for treating Hunter syndrome comprising:

20. 13. Use of the pharmaceutical composition of claim 1 for treating Hunter syndrome.

21. 13. Use of the pharmaceutical composition of claim 1 for the manufacture of a medicament for treating Hunter Syndrome.